Cargando…

Issues of methods and interpretation in the National Cancer Institute formaldehyde cohort study

In 2004, the International Agency for Research on Cancer (IARC) reclassified formaldehyde (FA) from a probable (Group 2A) to a known human carcinogen (Group 1) citing results for nasopharyngeal cancer (NPC) mortality from the follow-up through 1994 of the National Cancer Institute formaldehyde cohor...

Descripción completa

Detalles Bibliográficos
Autores principales: Marsh, Gary M, Morfeld, Peter, Collins, James J, Symons, James Morel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030030/
https://www.ncbi.nlm.nih.gov/pubmed/24855485
http://dx.doi.org/10.1186/1745-6673-9-22
_version_ 1782317319186284544
author Marsh, Gary M
Morfeld, Peter
Collins, James J
Symons, James Morel
author_facet Marsh, Gary M
Morfeld, Peter
Collins, James J
Symons, James Morel
author_sort Marsh, Gary M
collection PubMed
description In 2004, the International Agency for Research on Cancer (IARC) reclassified formaldehyde (FA) from a probable (Group 2A) to a known human carcinogen (Group 1) citing results for nasopharyngeal cancer (NPC) mortality from the follow-up through 1994 of the National Cancer Institute formaldehyde cohort study. To the contrary, in 2012, the Committee for Risk Assessment of the European Chemicals Agency disagreed with the proposal to classify FA as a known human carcinogen (Carc. 1A), proposing a lower but still protective category, namely as a substance which is presumed to have carcinogenic potential for humans (Carc. 1B). Thus, U.S. and European regulatory agencies currently disagree about the potential human carcinogenicity of FA. In 2013, the National Cancer Institute reported results from their follow-up through 2004 of the formaldehyde cohort and concluded that the results continue to suggest a link between FA exposure and NPC. We discuss in this commentary why we believe that this interpretation is neither consistent with the available data from the most recent update of the National Cancer Institute cohort study nor with other research findings from that cohort, other large cohort studies and the series of publications by some of the current authors, including an independent study of one of the National Cancer Institute’s study plants. Another serious concern relates to the incorrectness of the data from the follow-up through 1994 of the National Cancer Institute study stemming from incomplete mortality ascertainment. While these data were corrected by the National Cancer Institute in subsequent supplemental publications, incorrect data from the original publications have been cited extensively in recent causal evaluations of FA, including IARC. We conclude that the NCI publications that contain incorrect data from the incomplete 1994 mortality follow-up should be retracted entirely or corrected via published errata in the corresponding journals, and efforts should be made to re-analyze data from the 2004 follow-up of the NCI cohort study.
format Online
Article
Text
id pubmed-4030030
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40300302014-05-23 Issues of methods and interpretation in the National Cancer Institute formaldehyde cohort study Marsh, Gary M Morfeld, Peter Collins, James J Symons, James Morel J Occup Med Toxicol Commentary In 2004, the International Agency for Research on Cancer (IARC) reclassified formaldehyde (FA) from a probable (Group 2A) to a known human carcinogen (Group 1) citing results for nasopharyngeal cancer (NPC) mortality from the follow-up through 1994 of the National Cancer Institute formaldehyde cohort study. To the contrary, in 2012, the Committee for Risk Assessment of the European Chemicals Agency disagreed with the proposal to classify FA as a known human carcinogen (Carc. 1A), proposing a lower but still protective category, namely as a substance which is presumed to have carcinogenic potential for humans (Carc. 1B). Thus, U.S. and European regulatory agencies currently disagree about the potential human carcinogenicity of FA. In 2013, the National Cancer Institute reported results from their follow-up through 2004 of the formaldehyde cohort and concluded that the results continue to suggest a link between FA exposure and NPC. We discuss in this commentary why we believe that this interpretation is neither consistent with the available data from the most recent update of the National Cancer Institute cohort study nor with other research findings from that cohort, other large cohort studies and the series of publications by some of the current authors, including an independent study of one of the National Cancer Institute’s study plants. Another serious concern relates to the incorrectness of the data from the follow-up through 1994 of the National Cancer Institute study stemming from incomplete mortality ascertainment. While these data were corrected by the National Cancer Institute in subsequent supplemental publications, incorrect data from the original publications have been cited extensively in recent causal evaluations of FA, including IARC. We conclude that the NCI publications that contain incorrect data from the incomplete 1994 mortality follow-up should be retracted entirely or corrected via published errata in the corresponding journals, and efforts should be made to re-analyze data from the 2004 follow-up of the NCI cohort study. BioMed Central 2014-05-16 /pmc/articles/PMC4030030/ /pubmed/24855485 http://dx.doi.org/10.1186/1745-6673-9-22 Text en Copyright © 2014 Marsh et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/4.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Commentary
Marsh, Gary M
Morfeld, Peter
Collins, James J
Symons, James Morel
Issues of methods and interpretation in the National Cancer Institute formaldehyde cohort study
title Issues of methods and interpretation in the National Cancer Institute formaldehyde cohort study
title_full Issues of methods and interpretation in the National Cancer Institute formaldehyde cohort study
title_fullStr Issues of methods and interpretation in the National Cancer Institute formaldehyde cohort study
title_full_unstemmed Issues of methods and interpretation in the National Cancer Institute formaldehyde cohort study
title_short Issues of methods and interpretation in the National Cancer Institute formaldehyde cohort study
title_sort issues of methods and interpretation in the national cancer institute formaldehyde cohort study
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4030030/
https://www.ncbi.nlm.nih.gov/pubmed/24855485
http://dx.doi.org/10.1186/1745-6673-9-22
work_keys_str_mv AT marshgarym issuesofmethodsandinterpretationinthenationalcancerinstituteformaldehydecohortstudy
AT morfeldpeter issuesofmethodsandinterpretationinthenationalcancerinstituteformaldehydecohortstudy
AT collinsjamesj issuesofmethodsandinterpretationinthenationalcancerinstituteformaldehydecohortstudy
AT symonsjamesmorel issuesofmethodsandinterpretationinthenationalcancerinstituteformaldehydecohortstudy